Boule Diagnostics AB (publ)
Boule Diagnostics AB (publ) develops, manufactures, and markets instruments and consumable products for blood diagnostics in the United States of America, Asia, Eastern Europe, Latin America, Western Europe, Africa, and the Middle East. The company provides hematology analyzers, reagents, controls, and calibrators, under the Swelab, Medonic, and Quintus brands; and veterinary hematology and clini… Read more
Boule Diagnostics AB (publ) (BDABF) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2024: 0.020x
Based on the latest financial reports, Boule Diagnostics AB (publ) (BDABF) has a cash flow conversion efficiency ratio of 0.020x as of September 2024.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($5.20 Million) by net assets ($254.90 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Boule Diagnostics AB (publ) - Cash Flow Conversion Efficiency Trend (2014–2023)
This chart illustrates how Boule Diagnostics AB (publ)'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Boule Diagnostics AB (publ) Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Boule Diagnostics AB (publ) ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Text S.A.
PINK:LCHTF
|
0.302x |
|
PropertyGuru Group Ltd
NYSE:PGRU
|
0.026x |
|
NEXT FIFTEEN LS-025
F:8LS
|
N/A |
|
Centum Electronics Limited
NSE:CENTUM
|
0.140x |
|
Hanilcmt Co Ltd
KO:300720
|
0.053x |
|
HAYPP GROUP AB
F:8QG0
|
N/A |
|
Farglory Life Insurance Co. Ltd.
TWO:5859
|
0.073x |
|
XiAn Dagang Road Machinery Co
SHE:300103
|
-0.002x |
Annual Cash Flow Conversion Efficiency for Boule Diagnostics AB (publ) (2014–2023)
The table below shows the annual cash flow conversion efficiency of Boule Diagnostics AB (publ) from 2014 to 2023.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2023-12-31 | $475.10 Million | $35.65 Million | 0.075x | +404.41% |
| 2022-12-31 | $462.50 Million | $-11.40 Million | -0.025x | -116.84% |
| 2021-12-31 | $295.74 Million | $43.28 Million | 0.146x | -47.61% |
| 2020-12-31 | $269.30 Million | $75.24 Million | 0.279x | +72.30% |
| 2019-12-31 | $332.87 Million | $53.98 Million | 0.162x | +115.26% |
| 2018-12-31 | $300.86 Million | $22.66 Million | 0.075x | -65.83% |
| 2017-12-31 | $261.77 Million | $57.72 Million | 0.220x | +154.89% |
| 2016-12-31 | $229.76 Million | $19.88 Million | 0.087x | -26.95% |
| 2015-12-31 | $188.51 Million | $22.32 Million | 0.118x | -35.03% |
| 2014-12-31 | $169.99 Million | $30.98 Million | 0.182x | -- |